MoS Health Anupriya Patel released the 7th edition of the National Formulary of India (NFI 2026), covering 653 drugs, and announced the Biovigilance Programme of India in New Delhi on 21 September 2026.
The Biovigilance Programme, approved by the Government of India, will be led by the Indian Pharmacopoeia Commission (IPC) to track adverse events from medicines and biological products used in organ and tissue transplantation, for both donors and recipients.
NFI 2026 has 34 chapters and 20 appendices; its 653 drugs include 42 fixed-dose combinations and 30 immunologicals, and it is also available digitally as NFI Online.
Also released: a hospital guidance document on reporting medical-device adverse events and the iOS version of the ADR-PvPI 2.0 app.
The launches came during the 6th National Pharmacovigilance Week (17-23 September 2026); India now ranks 8th in contributions to the WHO global safety database, up from 123rd in 2009-2014.
Monitor adverse drug reactions and promote safe use of medicines
Key: Started 14 July 2010 with AIIMS New Delhi as National Coordination Centre; moved to IPC Ghaziabad on 15 April 2011; about 1,150 ADR monitoring centres
Track adverse reactions linked to blood transfusion
Key: Launched 10 December 2012; National Coordinating Centre at the National Institute of Biologicals, Noida, working with IPC
Track adverse events from medical devices
Key: Launched 6 July 2015 at IPC, which is its National Coordination Centre; the new hospital guidance document serves this programme
Report, assess, monitor and prevent adverse events from medicines and biological products used in organ and tissue transplantation
Key: Approved in 2026 and announced on 21 September 2026; IPC in the lead role; covers products given to both donors and recipients
Autonomous institution of the Ministry of Health and Family Welfare (set up 2005, fully operational from 1 January 2009); publishes the Indian Pharmacopoeia and the National Formulary of India, and is the National Coordination Centre for PvPI and MvPI
Ministry of Health institute for quality control of biologicals; National Coordinating Centre of the Haemovigilance Programme
Statutory regulator of pharmacy education under the Pharmacy Act, 1948; asked by IPC to get PharmD colleges to take part in the NFI launch
The Indian Pharmacopoeia, published by IPC, is the official book of drug standards under this Act. The NFI, by contrast, is a prescribing reference for rational use of medicines, not a legal standard.
Constitutes the Pharmacy Council of India, which regulates the PharmD and other pharmacy courses whose students are a target audience of the NFI.
First edition of the National Formulary of India
Pharmacovigilance Programme of India starts, NCC at AIIMS New Delhi
PvPI National Coordination Centre shifts to IPC, Ghaziabad
Haemovigilance Programme of India launched
Materiovigilance Programme of India launched at IPC
6th edition of the NFI
6th National Pharmacovigilance Week
NFI 2026 (7th edition) released; Biovigilance Programme of India announced
GS Paper 2 > Health: government policies and interventions, regulatory institutions
General Awareness > Government schemes and bodies (health)
General Awareness > Government initiatives
Detection, assessment and prevention of adverse effects of medicines.
Monitoring of adverse events caused by medical devices.
Monitoring of adverse events from biological materials and products used in transplantation, covering donors and recipients.
A reference listing of medicines with guidance on their rational use - distinct from a pharmacopoeia, which sets legal quality standards.